Business Description
Senti Biosciences Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US81726A2096
Total Employee Number:
39Description
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.47 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 7.46 | |||||
Debt-to-EBITDA | -0.35 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -17.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -90.7 | |||||
3-Year EBITDA Growth Rate | 50.7 | |||||
3-Year EPS without NRI Growth Rate | 52.3 | |||||
3-Year FCF Growth Rate | 59.5 | |||||
3-Year Book Growth Rate | -81.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 23.22 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 548.51 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.72 | |||||
9-Day RSI | 50.34 | |||||
14-Day RSI | 51.52 | |||||
3-1 Month Momentum % | 9.99 | |||||
6-1 Month Momentum % | -13.5 | |||||
12-1 Month Momentum % | -58.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.04 | |||||
Quick Ratio | 1.04 | |||||
Cash Ratio | 0.63 | |||||
Days Sales Outstanding | 1800.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -91.4 | |||||
Shareholder Yield % | 21.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -154810.53 | |||||
Net Margin % | -135650 | |||||
EBITDA Margin % | -143557.9 | |||||
FCF Margin % | -97039.47 | |||||
OCF Margin % | -97039.47 | |||||
ROE % | -327.13 | |||||
ROA % | -87.82 | |||||
ROIC % | -146.86 | |||||
3-Year ROIIC % | 3.43 | |||||
ROC (Joel Greenblatt) % | -199.46 | |||||
ROCE % | -126.52 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 515 | |||||
PB Ratio | 12.56 | |||||
Price-to-Tangible-Book | 12.88 | |||||
EV-to-EBIT | -0.72 | |||||
EV-to-Forward-EBIT | -0.91 | |||||
EV-to-EBITDA | -0.78 | |||||
EV-to-Revenue | 1112.76 | |||||
EV-to-Forward-Revenue | 422.85 | |||||
EV-to-FCF | -1.15 | |||||
Earnings Yield (Greenblatt) % | -138.89 | |||||
FCF Yield % | -114.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SNTI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Senti Biosciences Holdings Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.038 | ||
| EPS (TTM) ($) | -1.92 | ||
| Beta | 1.9098 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.33 | ||
| Volatility % | 81.43 | ||
| 14-Day RSI | 51.52 | ||
| 14-Day ATR ($) | 0.069089 | ||
| 20-Day SMA ($) | 1.018175 | ||
| 12-1 Month Momentum % | -58.62 | ||
| 52-Week Range ($) | 0.77017 - 2.88 | ||
| Shares Outstanding (Mil) | 31.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Senti Biosciences Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Senti Biosciences Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 26 days | ||
| General meeting for 2026 | 2026-07-16 08:00 | In 5 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.96 (-0.72%) | ||
| Annual report for 2025 | 2026-03-27 | 0.88 (-1.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 0.88 (-1.19%) | ||
| Guidance call for 2026 | 2026-03-09 14:20 | 0.96 (+5.45%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 15:10 | 0.94 (-3.67%) | ||
| Guidance call for 2025 | 2025-12-09 08:00 | 2.39 (+6.22%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.89 (-2.58%) |
Show
Entries
Senti Biosciences Holdings Inc Frequently Asked Questions
What is Senti Biosciences Holdings Inc(SNTI)'s stock price today?
The current price of SNTI is $1.03. The 52 week high of SNTI is $2.88 and 52 week low is $0.77.
When is next earnings date of Senti Biosciences Holdings Inc(SNTI)?
The next earnings date of Senti Biosciences Holdings Inc(SNTI) is 2026-08-07 Est..
Does Senti Biosciences Holdings Inc(SNTI) pay dividends? If so, how much?
Senti Biosciences Holdings Inc(SNTI) does not pay dividend.
Guru Commentaries on NAS:SNTI
No articles.
Press Release
Articles on Senti Biosciences Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers